<DOC>
	<DOCNO>NCT02652741</DOCNO>
	<brief_summary>Paediatric clinical trial 50 child , newborn less 6 year age , suffer heart failure due congenital heart disease , obtain paediatric pharmacokinetic pharmacodynamic data enalapril active metabolite enalaprilat treat 8 week enalapril form Orodispersible Minitablets ( ODMTs ) , describe dose exposure patient population .</brief_summary>
	<brief_title>Orodispersible Minitablets Enalapril Young Children With Heart Failure Due Congenital Heart Disease</brief_title>
	<detailed_description>This clinical trial one three clinical trial European Commission ( FP7 ) -funded `` LENA '' ( Labeling Enalapril Neonates Adolescents ) project : 50 child heart failure due congenital heart disease ( LENA-Work Package ( WP ) 09 Trial ) , 50 child heart failure due dilate cardiomyopathy ( LENA-WP08 Trial ) get treat optimal dose enalapril ODMTs 8 week thorough , individualise titration get invite join 10 month Safety Follow-up Study ( LENA-WP10 Trial ) . In WP09 Trial child age newborn less 6 year , naive enalapril treatment switch Angiotensin-Converting-Enzyme ( ACE ) -Inhibitor pre-treatment , receive Initial Dose investigate reaction 8 hour decision first dose level make . Always 7 day later next high dose give hospital , patient supervise 4 always 2 hour decision prescribe dose next dosing period make . In study target dose similar adult target dose ( 20 mg enalapril 70 year old adult result 0.282 mg/kg/day enalapril ) define . Enalapril ODMTs 0.25 mg 1 mg strength available allow individual dose titration scheme . Weight-dependently , pharmacokinetic ( PK ) pharmacodynamic ( PD ) data collect full PK/PD day 12 , respectively 6 hour , single PK/PD sample Dose Titration Visit bi-weekly Study Control Visit Last Visit 8 week treatment . Blood pressure renal monitoring perform visit decide dose level next treatment period . Pharmacogenomics metabolomics exploratory study add sub-study good understand underlie disease , progression well impact ACE-inhibition cardiac outcome renal function .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>Patients fulfil follow Inclusion Criteria enrol : Age birth less 6 year . Male female patient . Weight great 2.5 kg . Diagnosis heart failure due congenital heart disease require afterload reduction drug therapy . Subjects may naïve ACEInhibitors . Subjects already ACEInhibitors willing switch enalapril Orodispersible Minitablets . Patient and/or parent ( ) /legal representative provide write informed consent assent patient accord national legislation far achievable child . Patients fulfil follow Exclusion Criteria enrol trial : Neonates bear &lt; 37 week gestation . Severe heart failure and/or end stage heart failure preclude introduction continuation ACEInhibitor . Too low blood pressure , e.g . ˂P5 Uncorrected primary obstructive valvular disease , significant systemic ventricular outflow obstruction , dilate restrictive hypertrophic cardiomyopathy . Uncorrected severe peripheral stenosis large artery include severe coarctation aorta . Severe renal impairment serum creatinine &gt; 2x Upper Limit Normal ( ULN ) ( accord hospital 's test methodology ) History angioedema . Hypersensitivity ACEInhibitors . Concommitant medication : Dual ACEInhibitor therapy Renin inhibitor Angiotensin II antagonists NonSteroidal AntiInflammatory Drugs ( include ibuprofen ) except aspirin paracetamol Already enrol interventional trial investigational drug , unless interference current study show .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>